Sequential organ failure assessment score is an excellent operationalization of disease severity of adult patients with hospitalized community acquired pneumonia - results from the prospective observational PROGRESS study.


Journal

Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902

Informations de publication

Date de publication:
04 04 2019
Historique:
received: 05 09 2018
accepted: 07 01 2019
entrez: 6 4 2019
pubmed: 6 4 2019
medline: 18 12 2019
Statut: epublish

Résumé

CAP (Community acquired pneumonia) is frequent, with a high mortality rate and a high burden on health care systems. Development of predictive biomarkers, new therapeutic concepts, and epidemiologic research require a valid, reproducible, and quantitative measure describing CAP severity. Using time series data of 1532 patients enrolled in the PROGRESS study, we compared putative measures of CAP severity for their utility as an operationalization. Comparison was based on ability to correctly identify patients with an objectively severe state of disease (death or need for intensive care with at least one of the following: substantial respiratory support, treatment with catecholamines, or dialysis). We considered IDSA/ATS minor criteria, CRB-65, CURB-65, Halm criteria, qSOFA, PSI, SCAP, SIRS-Score, SMART-COP, and SOFA. SOFA significantly outperformed other scores in correctly identifying a severe state of disease at the day of enrollment (AUC = 0.948), mainly caused by higher discriminative power at higher score values. Runners-up were the sum of IDSA/ATS minor criteria (AUC = 0.916) and SCAP (AUC = 0.868). SOFA performed similarly well on subsequent study days (all AUC > 0.9) and across age groups. In univariate and multivariate analysis, age, sex, and pack-years significantly contributed to higher SOFA values whereas antibiosis before hospitalization predicted lower SOFA. SOFA score can serve as an excellent operationalization of CAP severity and is proposed as endpoint for biomarker and therapeutic studies. clinicaltrials.gov NCT02782013 , May 25, 2016, retrospectively registered.

Sections du résumé

BACKGROUND
CAP (Community acquired pneumonia) is frequent, with a high mortality rate and a high burden on health care systems. Development of predictive biomarkers, new therapeutic concepts, and epidemiologic research require a valid, reproducible, and quantitative measure describing CAP severity.
METHODS
Using time series data of 1532 patients enrolled in the PROGRESS study, we compared putative measures of CAP severity for their utility as an operationalization. Comparison was based on ability to correctly identify patients with an objectively severe state of disease (death or need for intensive care with at least one of the following: substantial respiratory support, treatment with catecholamines, or dialysis). We considered IDSA/ATS minor criteria, CRB-65, CURB-65, Halm criteria, qSOFA, PSI, SCAP, SIRS-Score, SMART-COP, and SOFA.
RESULTS
SOFA significantly outperformed other scores in correctly identifying a severe state of disease at the day of enrollment (AUC = 0.948), mainly caused by higher discriminative power at higher score values. Runners-up were the sum of IDSA/ATS minor criteria (AUC = 0.916) and SCAP (AUC = 0.868). SOFA performed similarly well on subsequent study days (all AUC > 0.9) and across age groups. In univariate and multivariate analysis, age, sex, and pack-years significantly contributed to higher SOFA values whereas antibiosis before hospitalization predicted lower SOFA.
CONCLUSIONS
SOFA score can serve as an excellent operationalization of CAP severity and is proposed as endpoint for biomarker and therapeutic studies.
TRIAL REGISTRATION
clinicaltrials.gov NCT02782013 , May 25, 2016, retrospectively registered.

Identifiants

pubmed: 30947753
doi: 10.1186/s13054-019-2316-x
pii: 10.1186/s13054-019-2316-x
pmc: PMC6450002
doi:

Banques de données

ClinicalTrials.gov
['NCT02782013']

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

110

Subventions

Organisme : Bundesministerium für Bildung und Forschung
ID : 01KI07110
Pays : International
Organisme : Bundesministerium für Bildung und Forschung
ID : 01KI07111
Pays : International
Organisme : Bundesministerium für Bildung und Forschung
ID : 01KI07113
Pays : International
Organisme : Bundesministerium für Bildung und Forschung
ID : 01KI07114
Pays : International
Organisme : Bundesministerium für Bildung und Forschung
ID : 01KI1010I
Pays : International
Organisme : Bundesministerium für Bildung und Forschung
ID : 01KI1010D
Pays : International
Organisme : Deutsche Zentrum für Lungenforschung
ID : 82DZLJ19A2
Pays : International

Investigateurs

Stefan Angermair (S)
Christoph Arntzen (C)
Lorenz Balke (L)
Robert Bals (R)
Michael Benzke (M)
Ayhan Berber (A)
Frank Bloos (F)
Martin Buchenroth (M)
Lea Deterding (L)
Nicolas Dickgreber (N)
Oleg Dmitriev (O)
Hermann Druckmiller (H)
Holger Flick (H)
Ulrike Föllmer (U)
Julia Freise (J)
Carmen Garcia (C)
Sven Gläser (S)
Christian Grah (C)
Simone Hamberger (S)
Karsten Hartung (K)
Barabara Hauptmeier (B)
Matthias Held (M)
Frederik Hempel (F)
Iris Hering (I)
Carola Hobler (C)
Andreas Hocke (A)
Ursula Hoffmann (U)
Henning Kahnert (H)
Oliver Kanwar (O)
Lena Kappauf (L)
Charlotte Keller (C)
Nils Keller (N)
Walter Knüppel (W)
Eva Koch (E)
Martin Kolditz (M)
Christine Krollmann (C)
Cornelia Kropf-Sanchen (C)
Josefa Lehmke (J)
Christian Lensch (C)
Andreas Liebrich (A)
Achim Lies (A)
Katrin Ludewig (K)
Lena-Maria Makowski (LM)
Phillippr Mayer (P)
Brigitte Mayer (B)
Agata Mikolajewska (A)
Anne Moeser (A)
Thomas Müller (T)
Michaela Niebank (M)
Markus Niesen (M)
Tim Oqueka (T)
Wulf Pankow (W)
Judith Pannier (J)
Claus Peckelsen (C)
Mathias Plauth (M)
Mathias Pletz (M)
Jan Pluta (J)
Kalina Popkirova (K)
Jessicar Rademache (J)
Mirja Ramke (M)
Felix Rosenow (F)
Stefan Rüdiger (S)
Bernhard Ruf (B)
Jan Rupp (J)
Bernhard Schaaf (B)
Tom Schaberg (T)
Marianne Schelle (M)
Patrick Schmidt-Schridde (P)
Galina Schott (G)
Barbara Schröder (B)
Tetyana Shchetynska-Marinova (T)
Michael Simpfendörfer (M)
Thomas Spinner (T)
Norbert Suttorp (N)
Dorina Thiemig (D)
Daniel Thomas-Rüddel (D)
Markus Unnewehr (M)
Barbara Wagener (B)
Gudrun Wakonigg (G)
Deborah Wehde (D)
Hubert Wirtz (H)
None Charite Icu-Teams

Références

Am J Med. 1993 Feb;94(2):153-9
pubmed: 8430711
Thorax. 2010 Oct;65(10):878-83
pubmed: 20729231
Am J Respir Crit Care Med. 2017 Apr 1;195(7):906-911
pubmed: 27649072
Curr Opin Pulm Med. 2014 May;20(3):215-24
pubmed: 24614242
Thorax. 2015 Jun;70(6):551-8
pubmed: 25782758
BMC Pulm Med. 2016 Jul 28;16(1):108
pubmed: 27535544
N Engl J Med. 2014 Oct 23;371(17):1619-28
pubmed: 25337751
J Infect. 2013 Sep;67(3):169-84
pubmed: 23707875
Sci Rep. 2016 Mar 18;6:22911
pubmed: 26987602
Thorax. 2008 Aug;63(8):665-6
pubmed: 18663064
JAMA. 2001 Oct 10;286(14):1754-8
pubmed: 11594901
Anaesthesist. 2010 Apr;59(4):347-70
pubmed: 20414762
Cardiovasc Res. 1997 Jul;35(1):2-3
pubmed: 9302340
JAMA. 1998 May 13;279(18):1452-7
pubmed: 9600479
JAMA. 2017 Jan 17;317(3):290-300
pubmed: 28114553
Am J Respir Crit Care Med. 2006 Dec 1;174(11):1249-56
pubmed: 16973986
N Engl J Med. 1997 Jan 23;336(4):243-50
pubmed: 8995086
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72
pubmed: 17278083
Clin Microbiol Infect. 2013 Dec;19(12):1174-80
pubmed: 23438068
Thorax. 2003 May;58(5):377-82
pubmed: 12728155
J Intern Med. 2015 Aug;278(2):193-202
pubmed: 25597400
Thorax. 2013 Nov;68(11):1057-65
pubmed: 24130229
Crit Care. 2012 Jul 27;16(4):R141
pubmed: 22839689
Chest. 2006 Apr;129(4):968-78
pubmed: 16608946
Am J Respir Crit Care Med. 2013 Oct 15;188(8):985-95
pubmed: 23855620
Clin Infect Dis. 2008 Aug 1;47(3):375-84
pubmed: 18558884
Ann Intern Med. 2014 Jan 21;160(2):122-31
pubmed: 24592497
Arch Intern Med. 2007 Aug 13-27;167(15):1655-63
pubmed: 17698689
Crit Care Med. 2004 May;32(5 Suppl):S209-13
pubmed: 15118519
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
Mediators Inflamm. 2013;2013:490346
pubmed: 24453422
Ann Intern Med. 2011 Apr 19;154(8):JC4-13
pubmed: 21502639
Prehosp Emerg Care. 2017 Jul-Aug;21(4):489-497
pubmed: 28121217
Eur Respir J. 2013 Apr;41(4):974-84
pubmed: 23018905

Auteurs

Peter Ahnert (P)

University of Leipzig, Institute for Medical Informatics, Statistics and Epidemiology (IMISE), Härtelstr. 16-18, 04107, Leipzig, Germany. peter.ahnert@imise.uni-leipzig.de.

Petra Creutz (P)

Department of Infectious Disease and Respiratory Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Virchowklinikum, Augustenburgerplatz 1, 13353, Berlin, Germany.

Katrin Horn (K)

University of Leipzig, Institute for Medical Informatics, Statistics and Epidemiology (IMISE), Härtelstr. 16-18, 04107, Leipzig, Germany.

Fabian Schwarzenberger (F)

Faculty of Informatics / Mathematics, HTW Dresden University of Applied Sciences, Friedrich-List-Platz 1, 01069, Dresden, Germany.

Michael Kiehntopf (M)

Jena University Hospital, Integrated Biobank Jena (IBBJ) and Institute of Clinical Chemistry and Laboratory Diagnostics, Am Klinikum 1, 07740, Jena, Germany.

Hamid Hossain (H)

Technische Hochschule Mittelhessen, University of Applied Sciences, Life Science Engineering, Wiesenstr. 14, 35390, Gießen, Germany.

Michael Bauer (M)

Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany.

Frank Martin Brunkhorst (FM)

Center for Clinical Studies and Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany.

Konrad Reinhart (K)

Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany.

Uwe Völker (U)

Department Functional Genomics, Interfaculty Institute of Genetics and Functional Genomics, University Medicine Greifswald, Felix-Hausdorff-Str. 8, 17475, Greifswald, Germany.

Trinad Chakraborty (T)

University Hospital Giessen, Institute for Medical Microbiology, Schubertstr. 81, 35392, Gießen, Germany.

Martin Witzenrath (M)

Department of Infectious Disease and Respiratory Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.

Markus Löffler (M)

Department of Infectious Disease and Respiratory Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.

Norbert Suttorp (N)

Department of Infectious Disease and Respiratory Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.

Markus Scholz (M)

University of Leipzig, Institute for Medical Informatics, Statistics and Epidemiology (IMISE), Härtelstr. 16-18, 04107, Leipzig, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH